OMAHA, Neb., May 4, 2011 /PRNewswire/ -- Transgenomic, Inc. (OTC/BB: TBIO) announced a significant enhancement to its FAMILION Brugada Syndrome (BrS) test panel at the 2011 Heart Rhythm Society meeting in San Francisco. The expanded panel includes analysis of 9 genes and broadens the test indication to include other J-wave syndromes, including Early Repolarization Syndrome.
"The addition of two newly identified J-wave syndrome genes, KCND3 and KCNJ8, reflects Transgenomic's commitment to translating new genetic advances into clinical practice," said Benjamin Salisbury, Ph.D., Vice President of Clinical Genetics at Transgenomic. "The renaming of the FAMILION BrS Test to the FAMILION BrS/J-Wave Test acknowledges the growing understanding that Brugada Syndrome is part of a spectrum of disorders with similar clinical presentations and a shared genetic basis that have been collectively termed J-wave syndromes."
The introduction of a newly enhanced test for BrS and other J-wave syndromes marks the fourth significant test launched or expanded in the FAMILION family of genetic tests over the past 6 months. The comprehensive and evolving menu of FAMILION genetic tests, as well as participation in primary research, demonstrates the Company's commitment to setting the standard for cardiac genetic testing and its support of the clinical community.
"We are excited to see the continued interest and growth in the FAMILION line of cardiac genetic tests," said Craig Tuttle, CEO of Transgenomic. "The integration of the FAMILION brand into the Transgenomic family has strengthened our outlook and continues to position the company for greater success in the future."
About the FAMILION Tests
The FAMILION family of tests detects genetic mutations that can cause cardiac channelopathies, cardiomyopathies, and other
|SOURCE Transgenomic, Inc.|
Copyright©2010 PR Newswire.
All rights reserved